RecruitingHeart Failure and Reduced Ejection FractionFunctional Mitral Regurgitation
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multi-center, prospective, observational study designed to evaluate the impact of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100 evaluable at 6 months of follow-up. Enrollment will occur at up to eight centers.
Sponsor: Minneapolis Heart Institute Foundation
You may qualify if…
- ✓ 1\. Adult patients (≥ 18 years old) with heart failure and reduced ejection fraction (LVEF \< 50% defined by echocardiography), medically and device-optimized according to guidelines, with significant FMR undergoing TEER with FDA-approved MitraClip device (Abbott Structural, USA)
You may not qualify if…
- ✕ 1. Concomitant PCI and TEER
- ✕ 2. Congenital heart disease
- ✕ 3. Stage D heart failure
- ✕ 4. Uncontrolled atrial fibrillation
- ✕ 5. Pregnancy
- ✕ 6. \> moderate tricuspid regurgitation
- ✕ 7. \>moderate aortic regurgitation or stenosis
- ✕ 8. Contraindications or unable to undergo CMR
Where it's recruiting
Source: ClinicalTrials.gov · NCT07131631 · last updated 2025-12-23